ArticlePloS one2025
A large-scale trial in Chennai, India shows effective reduction of Anopheles stephensi populations by the biolarvicide Natular.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biolarvicides present an environmentally safer alternative to chemical larvicides, demonstrating selectivity against target species. However, the available options for biolarvicide use in mosquito control remain limited. This study aimed to assess the effectiveness of three formulations of the biolarvicide Natular, namely the 20.6% Emulsifiable Concentrate (EC), 2.5% G30 granular, and 7.48% tablet (DT) for direct application, against Anopheles stephensi in large-scale field trials conducted in Chennai, India. When the 7.48% DT formulation was applied at a rate of 1 tablet per 200 L in overhead tanks with An. stephensi breeding sites, on an average, led to a > 90-100% reduction in An. stephensi larval and pupal density for a duration of 8-9 weeks in rainy, winter and summer seasons. Similarly, the 2.5% G30 formulation, at a concentration of 0.074 mg (AI)/L in overhead tanks, impressively suppressed An. stephensi larval and pupal density by 91-100% for 4-5 weeks in three seasons. The application of the 20.6% EC formulation at 0.073 mg (AI)/L in overhead tanks achieved a remarkable 100% reduction in larval and pupal density for 2 weeks in all seasons. The Natular 7.48% DT formulation is well-suited for An. stephensi larval control at 1 tablet per 200 L with an 8-week application interval. The 2.5% G30 formulation is recommended at 0.074 mg (AI)/L at 4-week intervals. Meanwhile, the 20.6% EC formulation can effectively control An. stephensi at 0.073 mg (AI)/L with fortnightly application intervals. These Natular formulations serve as potent biolarvicides, offering a valuable tool for An. stephensi control within the Integrated Vector Management (IVM) program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.